Sio Gene Therapies Inc. Common Stock
SIOX
SIOX was delisted on the 22nd of March, 2023.
40 hedge funds and large institutions have $33.7M invested in Sio Gene Therapies Inc. Common Stock in 2020 Q2 according to their latest regulatory filings, with 6 funds opening new positions, 12 increasing their positions, 8 reducing their positions, and 8 closing their positions.
50% more repeat investments, than reductions
Existing positions increased: 12 | Existing positions reduced: 8
19% more capital invested
Capital invested by funds: $28.4M → $33.7M (+$5.28M)
5% less funds holding
Funds holding: 42 → 40 (-2)
25% less first-time investments, than exits
New positions opened: 6 | Existing positions closed: 8
44% less call options, than puts
Call options by funds: $246K | Put options by funds: $440K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Hudson Bay Capital Management
Stamford,
Connecticut
|
+$1.04M |
| 2 |
Renaissance Technologies
New York
|
+$699K |
| 3 |
D.E. Shaw & Co
New York
|
+$214K |
| 4 |
BBVA
Banco Bilbao Vizcaya Argentaria
Madrid,
Spain
|
+$160K |
| 5 |
Two Sigma Investments
New York
|
+$132K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Adage Capital Partners
Boston,
Massachusetts
|
-$305K |
| 2 |
Citadel Advisors
Miami,
Florida
|
-$282K |
| 3 |
SFM
Sphera Funds Management
Tel Aviv,
Israel
|
-$234K |
| 4 |
CM
Caption Management
Oklahoma City,
Oklahoma
|
-$160K |
| 5 |
Bank of America
Charlotte,
North Carolina
|
-$69.6K |
SIOX Hedge Fund Activity: Q2 2020 in Review
40 of the 4,877 institutional investors tracked by Wall St. Rank reported a position in Sio Gene Therapies Inc. Common Stock (SIOX) for Q2 2020, worth a combined $33.7M — up 19% from $28.4M a quarter earlier.
Sellers outnumbered buyers: 8 funds closed out of SIOX and 6 opened new positions — a net loss of 2 holders — while 8 trimmed existing stakes and 12 added.
The largest buyer was Hudson Bay Capital Management, adding an estimated $1.04M. The largest seller was Adage Capital Partners, exiting entirely with an estimated $305K sold.
- 40 institutional investors held Sio Gene Therapies Inc. Common Stock (SIOX) as of Q2 2020, down from 42 in Q1 2020.
- Funds reported $33.7M of Sio Gene Therapies Inc. Common Stock stock for Q2 2020, up 19% quarter-over-quarter.
- 6 funds opened new Sio Gene Therapies Inc. Common Stock positions in Q2 2020 and 8 closed out, a net change of -2 holders.
- The largest Sio Gene Therapies Inc. Common Stock buyer in Q2 2020 was Hudson Bay Capital Management, an estimated $1.04M added.
- The largest Sio Gene Therapies Inc. Common Stock seller in Q2 2020 was Adage Capital Partners, an estimated $305K sold.
Based on aggregated 13F filings for Q2 2020.